While canonical HDAC inhibitors are ineffective, SIRT3 inhibitor YC8–02 alone showed remarkable cytotoxicity for DLBCL cells both in vivo and in vitro; at the same time, genetic targeting of Sirt3 reduced proliferation of DLBCL cell lines and tumour growth in spontaneous mouse models of MYC-induced lymphomagenesis [153]. Here, SIRT3 is linked to diffuse large B-cell lymphoma.